Human miR223 promoter as a novel myelo-specific promoter for chronic granulomatous disease gene therapy

Human Gene Therapy Methods

Volumn 24, Issue 3, 2013, Pages 151-159

  Brendel, Christian ^a   Hänseler, Walther ^b   Wohlgensinger, Vital ^b   Bianchi, Matteo ^b   Tokmak, Serap ^a   Chen Wichmann, Linping ^a   Kuzmenko, Elena ^b   Cesarovic, Nikola ^c   Nicholls, Flora ^c   Reichenbach, Janine ^b   Seger, Reinhard ^b   Grez, Manuel ^a   Siler, Ulrich ^b  

^a INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; GLYCOPROTEIN GP 91; GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; MICRORNA 223; PROTEIN P47;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERICIDAL ACTIVITY; CELL DIFFERENTIATION; CHRONIC GRANULOMATOUS DISEASE; CONTROLLED STUDY; ESCHERICHIA COLI; GENE TRANSFER; GRANULOCYTE; HEMATOPOIETIC STEM CELL; LYMPHOCYTE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; GENETIC THERAPY; GENETIC VECTORS; GRANULOCYTES; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; LENTIVIRUS; MEMBRANE GLYCOPROTEINS; MICE; MICE, KNOCKOUT; MICRORNAS; NADPH OXIDASE; PHAGOCYTOSIS; PROMOTER REGIONS, GENETIC;

ESCHERICHIA COLI;

EID: 84879334117     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2012.157     Document Type: Article

References (44)

1. Aiuti, A., Slavin, S., Aker, M., et al. (2002). Correction of ADASCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296, 2410-2413. (Pubitemid 34734219)
2. Allantaz, F., Cheng, D.T., Bergauer, T., et al. (2012). Expression profiling of human immune cell subsets identifies miRNAmRNA regulatory relationships correlated with cell typespecific expression. PLoS One 7, e29979.
3. Bainbridge, J.W., Smith, A.J., Barker, S.S., et al. (2008). Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med. 358, 2231-2239. (Pubitemid 351724452)
4. Bianchi, M., Hakkim, A., Brinkmann, V., et al. (2009). Restoration of NET formation by gene therapy in CGD controls aspergillosis. Blood 114, 2619-2622.
5. Bianchi,M., Niemiec,M.J., Siler, U., et al. (2011). Restoration of anti-Aspergillus defense by neutrophil extracellular traps in human chronic granulomatous disease after gene therapy is calprotectindependent. J. Allergy Clin. Immunol. 127, 1243-1252 e7.
6. Boztug, K., Schmidt, M., Schwarzer, A., et al. (2010). Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N. Engl. J. Med. 363, 1918-1927.
7. Brendel, C., Muller-Kuller, U., Schultze-Strasser, S., et al. (2011). Physiological regulation of transgene expression by a lentiviral vector containing the A2UCOE linked to a myeloid promoter. Gene Ther. 19, 1018-1029.
8. Brown, B.D., Gentner, B., Cantore, A., et al. (2007). Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat. Biotechnol. 25, 1457-1467. (Pubitemid 350233144)
9. Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C.C., et al. (2009). Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326, 818-823.
10. Cavazzana-Calvo, M., Hacein-Bey, S., De Saint Basile, G., et al. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288, 669-672. (Pubitemid 30241569)
11. Cavazzana-Calvo, M., Payen, E., Negre, O., et al. (2010). Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 467, 318-322.
12. Cesana, D., Sgualdino, J., Rudilosso, L., et al. (2012). Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations. J. Clin. Invest. 122, 1667-1676.
13. Chambers, S.M., Boles, N.C., Lin, K.Y., et al. (2007). Hematopoietic fingerprints: An expression database of stem cells and their progeny. Cell Stem Cell 1, 578-591.
14. Dinauer, M.C., Gifford, M.A., Pech, N., et al. (2001). Variable correction of host defense following gene transfer and bone marrow transplantation in murine X-linked chronic granulomatous disease. Blood 97, 3738-3745.
15. Dykstra, B., Kent, D., Bowie, M., et al. (2007). Long-term propagation of distinct hematopoietic differentiation programs in vivo. Cell Stem Cell 1, 218-229. (Pubitemid 47215588)
16. Fazi, F., Racanicchi, S., Zardo, G., et al. (2007). Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. Cancer Cell 12, 457-466. (Pubitemid 350046404)
17. Fehse, B., Kustikova, O.S., Bubenheim, M., and Baum, C. (2004). Pois(s)on - it's a question of dose. Gene Ther. 11, 879-881.
18. Fukao, T., Fukuda, Y., Kiga, K., et al. (2007). An evolutionarily conserved mechanism for microRNA-223 expression revealed by microRNA gene profiling. Cell 129, 617-631. (Pubitemid 46660972)
19. Gentner, B., Visigalli, I., Hiramatsu, H., et al. (2010). Identification of hematopoietic stem cell-specific miRNAs enables gene therapy of globoid cell leukodystrophy. Sci. Transl. Med. 2, 58ra84.
20. Gerrits, A., Dykstra, B., Kalmykowa, O.J., et al. (2010). Cellular barcoding tool for clonal analysis in the hematopoietic system. Blood 115, 2610-2618.
21. Grez, M., Reichenbach, J., Schwable, J., et al. (2011). Gene therapy of chronic granulomatous disease: The engraftment dilemma. Mol. Ther. 19, 28-35.
22. Hamers, M.N., Bot, A.A.M., Weening, R.S., et al. (1984). Kinetics and mechanism of the bactericidal action of human neutrophils against Escherichia coli. Blood 64, 635-641. (Pubitemid 14073481)
23. He, W., Qiang, M., Ma, W., et al. (2006). Development of a synthetic promoter for macrophage gene therapy. Hum. Gene Ther. 17, 949-959. (Pubitemid 46076755)
24. Heydemann, A., Warming, S., Clendenin, C., et al. (2000). A minimal c-fes cassette directs myeloid-specific expression in transgenic mice. Blood 96, 3040-3048.
25. Johnnidis, J.B., Harris, M.H., Wheeler, R.T., et al. (2008). Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature 451, 1125-1129. (Pubitemid 351317447)
26. Kaplitt, M.G., Feigin, A., Tang, C., et al. (2007). Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: An open label, phase I trial. Lancet 369, 2097-2105. (Pubitemid 46935946)
27. Kuhns, D.B., Alvord, W.G., Heller, T., et al. (2010). Residual NADPH oxidase and survival in chronic granulomatous disease. N. Engl. J. Med. 363, 2600-2610.
28. Kustikova, O.S., Schiedlmeier, B., Brugman, M.H., et al. (2009 Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis. Mol. Ther. 17, 1537-1547.
29. Landgraf, P., Rusu, M., Sheridan, R., et al. (2007). A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 129, 1401-1414. (Pubitemid 46970709)
30. Mavilio, F., Pellegrini, G., Ferrari, S., et al. (2006). Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat. Med. 12, 1397-1402. (Pubitemid 44924498)
31. Modlich, U., Navarro, S., Zychlinski, D., et al. (2009). Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol. Ther. 17, 1919-1928.
32. Montini, E., Cesana, D., Schmidt, M., et al. (2009). The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J. Clin. Invest. 119, 964-975.
33. Morgan, R.A., Dudley, M.E., Wunderlich, J.R., et al. (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129.
34. Ott, M.G., Schmidt, M., Schwarzwaelder, K., et al. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 12, 401-409.
35. Porter, D.L., Levine, B.L., Kalos, M., et al. (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733.
36. Rada, B.K., Geiszt, M., Kaldi, K., et al. (2004). Dual role of phagocytic NADPH oxidase in bacterial killing. Blood 104, 2947-2953. (Pubitemid 39434986)
37. Santilli, G., Almarza, E., Brendel, C., et al. (2011). Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol. Ther. 19, 122-132.
38. Seger, R.A. (2008). Modern management of chronic granulomatous disease. Br. J. Haematol. 140, 255-266.
39. Stein, S., Ott, M.G., Schultze-Strasser, S., et al. (2010). Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med. 16, 198-204.
40. Toscano, M.G., Romero, Z., Munoz, P., et al. (2011). Physiological and tissue-specific vectors for treatment of inherited diseases. Gene Ther. 18, 117-127.
41. Urban, C.F., Ermert, D., Schmid, M., et al. (2009). Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans. PLoS Pathog. 5, e1000639.
42. Van Den Berg, J.M., Van Koppen, E., Ahlin, A., et al. (2009). Chronic granulomatous disease: The European experience. PLoS One 4, e5234.
43. Wohlgensinger, V., Seger, R., Ryan, M.D., et al. (2010). Signed outside: A surface marker system for transgenic cytoplasmic proteins. Gene Ther. 17, 1193-1199.
44. Zychlinski, D., Schambach, A., Modlich, U., et al. (2008). Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol. Ther. 16, 718-725. (Pubitemid 351426173) Wissenschaft und Kunst